Table of Contents o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-04321 ___________________________________ PROCEPT BIOROBOTICS CORPORATION (Exact name of registrant as specified in its charter) ___________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 10-K ___________________________________ (Mark ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Matt Bacso - VP, IR and Business Operations Reza Zadno - President and CEO Kevin Waters - EVP and CFO Conference Call Participants Craig Bijou - Bank of America Joshua Jennings - TD Cowen Matthew O'Brien - Piper Sandler Chris Pasquale - Nephron Research Brandon Vasquez - William Blair Nathan Treybeck - Wells Fargo Mike Kratky - Leerink Partners Operator Good day and thank you for ...

44 2024 Financial Guidance Actual 2023 Guidance FY241 Revenue : OPEX Growth Ratio 1.5x ~1.9x Total Revenue ($ Mil) Non-GAAP Reconciliations RECONCILIATION OF 2024 GAAP NET LOSS TO ADJUSTED EBITDA Guidance (in thousands) References 3. WATER U.S. pivotal trial 2014, Ortman, An Aging Nation: The Older Population in the United States Vuichoud, C, Loughlin, K. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015 Oct;22 Suppl 1:1-6. Vuichoud, C, Loughlin, K. Benign prostatic hype ...

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results SAN JOSE, Calif., February 27, 2024 -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2023. Recent Highlights "I am extremely proud of our commercial achievements in 2023," said Reza Zadno, Chief Executive Officer. "We succeeded in elevating the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT BioRobotics Corporation (Exact name of registrant as specified in its charter) Indicate by check mark whether ...

7 U.S. men actively MANAGED for BPH 12M All numbers are approximate. Vuichoud, C, Loughlin, K. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015 Oct;22 Suppl 1:1-6. Data on File, PROCEPT BioRobotics Total surgeries based on 2019 market data, representing pre-pandemic surgeries PHARMACEUTICAL FALLOUT C o p y r i g h t 2 0 2 3 P R O C E P T B i o R o b o t i c s C o r p o r a t i o n . A l l R i g h t s R e s e r v e d . REAL-TIME, MULTI-DIMENSIONAL VISUALIZATION OF THE EN ...

PROCEPT BioRobotics Corporation. (NASDAQ:PRCT) Q3 2023 Earnings Conference Call November 1, 2023 6:00 PM ET Company Participants Matt Bacso - VP, IR and Business Operations Reza Zadno - President and CEO Kevin Waters - EVP and CFO Conference Call Participants Craig Bijou - Bank of America Joshua Jennings - TD Cowen Matthew O'Brien - Piper Sandler Richard Newitter - Truist Securities Brandon Vasquez - William Blair Nathan Treybeck - Wells Fargo Mike Kratky - Leerink Partners Operator Good day and welcome to ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2023 Earnings Conference Call July 27, 2023 8:00 AM ET Company Participants Matt Bacso - VP, IR and Business Operations Reza Zadno - President and CEO Kevin Waters - EVP and CFO Conference Call Participants Craig Bijou - Bank of America Securities Joshua Jennings - TD Cowen Matthew Mishan - KeyBanc Richard Newitter - Truist Securities. Chris Pasquale - Nephron Research Neil Chatterji - B. Riley Nathan Treybeck - Wells Fargo Brandon Vazquez - William Blair Ope ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition peri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT BioRobotics Corporation (Exact name of registrant as specified in its charter) | Delaware | | | 26-0199180 | | --- | --- | -- ...